IS7407A - Afleysing lausnarsambanda atorvastatínhálfkalsíums - Google Patents

Afleysing lausnarsambanda atorvastatínhálfkalsíums

Info

Publication number
IS7407A
IS7407A IS7407A IS7407A IS7407A IS 7407 A IS7407 A IS 7407A IS 7407 A IS7407 A IS 7407A IS 7407 A IS7407 A IS 7407A IS 7407 A IS7407 A IS 7407A
Authority
IS
Iceland
Prior art keywords
solvents
calcium
solution
atorvastatin semi
atorvastatin
Prior art date
Application number
IS7407A
Other languages
English (en)
Inventor
Aronhime Judith
Maidan-Hanoch Dalia
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS7407A publication Critical patent/IS7407A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04Calcium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7407A 2002-02-19 2004-08-17 Afleysing lausnarsambanda atorvastatínhálfkalsíums IS7407A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35849702P 2002-02-19 2002-02-19
PCT/US2003/005216 WO2003070665A2 (en) 2002-02-19 2003-02-19 Desolvating solvates of atorvastatin hemi-calcium

Publications (1)

Publication Number Publication Date
IS7407A true IS7407A (is) 2004-08-17

Family

ID=27757749

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7407A IS7407A (is) 2002-02-19 2004-08-17 Afleysing lausnarsambanda atorvastatínhálfkalsíums

Country Status (15)

Country Link
US (2) US7122681B2 (is)
EP (1) EP1465901A4 (is)
JP (4) JP4422488B2 (is)
KR (3) KR20090045420A (is)
CN (1) CN100379723C (is)
AU (1) AU2003213171A1 (is)
CA (1) CA2475123A1 (is)
HR (1) HRP20040767A2 (is)
IL (1) IL163594A0 (is)
IS (1) IS7407A (is)
MX (1) MXPA04007995A (is)
NO (1) NO20043829L (is)
PL (1) PL372241A1 (is)
WO (1) WO2003070665A2 (is)
ZA (1) ZA200406229B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
RU2412191C2 (ru) * 2004-07-16 2011-02-20 Лек Фармасьютиклз Д.Д. Продукты окислительной деструкции кальций аторвастатина
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006021882A1 (en) * 2004-08-25 2006-03-02 Pfizer Limited Triazolobenzodiazepines and their use as vasopressin antagonists
US20080009540A1 (en) * 2004-09-30 2008-01-10 Srinivasulu Gudipati Amorphous Atorvastatin Calcium
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
KR20080007561A (ko) * 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
KR102043337B1 (ko) 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
ES2879351T3 (es) 2016-02-25 2021-11-22 Asceneuron Sa Sales de derivados de piperazina obtenidas por adición de ácidos
US11261183B2 (en) * 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
RS64006B1 (sr) 2017-05-23 2023-03-31 H Lundbeck As Pirazol magl inhibitori
EA202190275A1 (ru) 2018-08-22 2021-08-02 Асенейрон С. А. Сукцинатные и фумаратные кислотно-аддитивные соли производных пиперазина, пригодные в качестве ингибиторов гликозидазы

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444129A (en) * 1891-01-06 Henry l
US4444129A (en) 1982-11-05 1984-04-24 Lecorp Method of drying fine coal particles
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
JPS59167676A (ja) 1983-03-11 1984-09-21 株式会社 大川原製作所 多室型流動層乾燥機
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
ES2167587T3 (es) * 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP1535613B1 (en) 1999-11-17 2010-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing a polymorphic form of atorvastatin calcium
DE60024133T2 (de) 1999-12-17 2006-08-03 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
IL149088A0 (en) 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A process for producing crystalline atorvastatin calcium
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma HEMICALCIC ATORVASTATIN FORM VII
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622697A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (is) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
AP1571A (en) * 2001-06-29 2006-02-10 Warner Lambert Co Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CN100471836C (zh) 2001-07-30 2009-03-25 雷迪实验室有限公司 托伐他汀钙晶型vi和vii
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
KR100724515B1 (ko) 2002-02-15 2007-06-04 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법

Also Published As

Publication number Publication date
KR20040086397A (ko) 2004-10-08
ZA200406229B (en) 2006-06-28
JP2013136630A (ja) 2013-07-11
US7122681B2 (en) 2006-10-17
CA2475123A1 (en) 2003-08-28
JP2009143957A (ja) 2009-07-02
IL163594A0 (en) 2005-12-18
WO2003070665A3 (en) 2004-02-12
PL372241A1 (en) 2005-07-11
WO2003070665A2 (en) 2003-08-28
CN100379723C (zh) 2008-04-09
KR20090045420A (ko) 2009-05-07
JP2009235100A (ja) 2009-10-15
MXPA04007995A (es) 2004-11-26
NO20043829L (no) 2004-09-13
CN1633439A (zh) 2005-06-29
US20030216584A1 (en) 2003-11-20
JP4422488B2 (ja) 2010-02-24
EP1465901A4 (en) 2006-02-01
US20070027328A1 (en) 2007-02-01
HRP20040767A2 (en) 2004-12-31
EP1465901A2 (en) 2004-10-13
JP2005523285A (ja) 2005-08-04
KR20090045419A (ko) 2009-05-07
AU2003213171A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
IS7407A (is) Afleysing lausnarsambanda atorvastatínhálfkalsíums
EP1660436A4 (en) cathepsin inhibitors
NO20044916L (no) Preparater av sulfinylacetamid
DK1519928T3 (da) Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
IS7833A (is) Efnasambönd með sameinaða heteróhringi
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
ATA5212002A (de) Teleskop
DE60323088D1 (de) Leberschützende wirkung der 10-o-p-hydroxybenzoylaucubin
FR2839258B1 (fr) Deambulateur-siege
DE602004030633D1 (de) Reinigung von Amidderivaten
FI20020094A7 (fi) Nefriinintapaisten yhdisteiden käyttö
SE0203348D0 (sv) Novel compounds
FI20021406A0 (fi) Densiinitapaisten yhdisteiden käyttö
UA6909S (uk) Комплект емблем
UA8904S (uk) Комплект етикеток
UA7418S (uk) Комплект етикеток
UA7807S (uk) Комплект етикеток
UA8155S (uk) Комплект етикеток
UA9821S (uk) Комплект етикеток
UA9242S (uk) Комплект етикеток
UA9239S (uk) Комплект етикеток
UA8496S (uk) Комплект етикеток
UA8270S (uk) Комплект етикеток
UA6746S (uk) Кобза чотириструнна
UA7077S (uk) Комплект етикеток